Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors - Concepedia

Concepedia

Publication | Open Access

Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors

DOI Full Paper Access

36

Citations

17

References

2022

Year

Matteo Santoni, Francesco Massari, Sergio Bracarda, Enrique Grande, Marc Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia,

European Urology Focus

UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorTyrosine Kinase InhibitorsPharmacotherapyFirst-line ImmunocombinationsCancer TreatmentOncologyRadiation Oncology

References

	Year	Citations

Page 1

Page 1